

Docket Number: 037003-0275681

Client Reference: 1995-30-0233CP2



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re The Application of ANDERSON et al.

Group Art Unit: 1644

Application No.: 09/576,424

Examiner: Phillip Gambel

Filed: May 22, 2000

Confirmation No.: 2393

For: TREATMENT OF CROHN'S DISEASE USING ANTI-CD80 ANTIBODIES THAT DO NOT INHIBIT THE BINDING OF CD80 ANTIGEN TO CTLA-4

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. These references were cited in European patent applications related to the present application. It is respectfully requested that the listed references be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue there from.

This Information Disclosure Statement is being filed with a Request for Continued Examination. No certification or fee is required.


Respectfully Submitted,

A handwritten signature in black ink, appearing to read "T. A. Cawley, Jr." with a stylized flourish at the end.

Thomas A. Cawley, Jr., Ph.D.  
Registration Number 40,944  
Customer Number: 5272

Date: October 28, 2003  
PILLSBURY WINTHROP LLP  
Telephone: (703) 905-2000  
Facsimile: (703) 905-2500  
P.O. Box 10500  
McLean, VA 22102  
TAC/CR:ntb

FORM PTO-1449 (modified)  
To: U.S. Department of Commerce  
(PW FORM PAT-1449)  
Patent and Trademark Office



Atty.  
Dkt. No.

M#

Client Ref.

037003-

0275681

1995-30-0233CP2

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

Applicant: ANDERSON et al.

Appln. No.: 09/576,424

Filing Date: May 22, 2000

Date: October 28, 2003

Page

1

of

1

Examiner: Phillip Gambel

Group Art Unit: 1644

## **U.S. PATENT DOCUMENTS**

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
AR						
BR						

## **FOREIGN PATENT DOCUMENTS**

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
					Enclosed	No	Enclose	No
CR	WO 87/01131	02/1987	PCT					
DR	WO 95/22619	08/1995	PCT					
ER	WO 96/40878A	12/1996	PCT					
FR								
GR								

## **OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)**

HR	European Search Report dated November 22, 1999, for EP Application No. 96922439, based on PCT Application No. PCT/US96/10053.
IR	European Search Report dated January 31, 2001, for EP Application No. 97913955, based on PCT Application No. PCT/US97/19906.
JR	Official Communication dated May 28, 2002, for EP Application No. 96922439, based on PCT Application No. PCT/US97/19906.
KR	Official Communication dated September 9, 2002, for EP Application No. 96922439, based on PCT Application No. PCT/US97/19906.
LR	Van Gool et al., "Synergy between cyclosporin A and a monoclonal antibody to B7 in blocking alloantigen-induced T-cell activation," 1994, <i>Blood</i> , 83(1):176-183.
MR	Nakajima et al., "Preferential dependence of autoantibody production in murine lupus on CD86 costimulatory molecule," 1995, <i>European Journal of Immunology</i> , 25(11):3060-9.
NR	Lenschow et al., "Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies," 1995, <i>Transplantation</i> , 60(10):1171-8.
OR	Lenschow et al., "Differential Effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the Nonobese Diabetic Mouse," 1995, <i>J Exp. Med.</i> , 181:1145-1155.
PR	Kuchroo et al., "B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy," 1995, <i>Cell</i> , 80:707-718.
QR	Wettendorff et al., "Generation of humanized Fab fragments of B7-24 mAb, an antibody with potential use in prevention of graft rejection and development of graft-versus-host-disease," 1995, <i>Med Fac Landbouww. Univ. Gent.</i> , 60(4):2057-2063.
RR	

Examiner

Date Considered:

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.